Targeting chaperones in transformed systems - a focus on Hsp90 and cancer

被引:79
作者
Chiosis, G [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Programme Mol Pharmacol & Chem, Dept Med, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
cancer; Hsp90; transformed system;
D O I
10.1517/14728222.10.1.37
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The molecular chaperone Hsp90 is a protein with important roles in maintaining the functional stability and viability of cells under a transforming pressure. Cancer cells harbour mutated oncogenic proteins or proteins with dysregulated function and the chaperone is required to maintain their folded and functionally active conformation. In addition, by chaperoning key proteins such as Raf-1, Akt, survivin and hTERT, Hsp90 regulates signalling pathways necessary for the growth, survival and limitless replicative potential of most tumours. Important elements of the apoptotic pathways are also regulated by Hsp90 Overall, these characteristics propose Hsp90 as an important target of whose inhibition may aim at a wide-range of oncogenic transformations. Several years into Hsp90 research have shed light into the feasibility, but also the limitations, of such an approach. In this review, the authors present the current understanding on the relevance and possibility of translating Hsp90 inhibitors into therapeutic agents in cancer therapy.
引用
收藏
页码:37 / 50
页数:14
相关论文
共 124 条
[21]   The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors [J].
Cheung, KMJ ;
Matthews, TP ;
James, K ;
Rowlands, MG ;
Boxall, KJ ;
Sharp, SY ;
Maloney, A ;
Roe, SM ;
Prodromou, C ;
Pearl, LH ;
Aherne, GW ;
McDonald, E ;
Workman, P .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (14) :3338-3343
[22]   Hsp90: the vulnerable chaperone [J].
Chiosis, G ;
Vilenchik, M ;
Kim, J ;
Solit, D .
DRUG DISCOVERY TODAY, 2004, 9 (20) :881-888
[23]   Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90 [J].
Chiosis, Gabriela ;
Lucas, Brian ;
Huezo, Henri ;
Solit, David ;
Basso, Andrea ;
Rosen, Neal .
CURRENT CANCER DRUG TARGETS, 2003, 3 (05) :371-376
[24]   Hsp90 potentiates the rapid evotution of new traits: Drug resistance in diverse fungi [J].
Cowen, LE ;
Lindquist, S .
SCIENCE, 2005, 309 (5744) :2185-2189
[25]   Hsp90 is essential in the filarial nematode Brugia pahangi [J].
Devaney, E ;
O'Neill, K ;
Harnett, W ;
Whitesell, L ;
Kinnaird, JH .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2005, 35 (06) :627-636
[26]   Imatinib as a paradigm of targeted therapies [J].
Druker, BJ .
ADVANCES IN CANCER RESEARCH, VOL 91, 2004, 91 :1-+
[27]   GHKL, an emergent ATPase/kinase superfamily [J].
Dutta, R ;
Inouye, M .
TRENDS IN BIOCHEMICAL SCIENCES, 2000, 25 (01) :24-28
[28]   Adenine derived inhibitors of the molecular chaperone HSP90 - SAR explained through multiple X-ray structures [J].
Dymock, B ;
Barril, X ;
Beswick, M ;
Collier, A ;
Davies, N ;
Drysdale, M ;
Fink, A ;
Fromont, C ;
Hubbard, RE ;
Massey, A ;
Surgenor, A ;
Wright, L .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (02) :325-328
[29]   Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design [J].
Dymock, BW ;
Barril, X ;
Brough, PA ;
Cansfield, JE ;
Massey, A ;
McDonald, E ;
Hubbard, RE ;
Surgenor, A ;
Roughley, SD ;
Webb, P ;
Workman, P ;
Wright, L ;
Drysdale, MJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (13) :4212-4215
[30]   Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts [J].
Eiseman, JL ;
Lan, J ;
Lagattuta, TF ;
Hamburger, DR ;
Joseph, E ;
Covey, JM ;
Egorin, MJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (01) :21-32